Vimarsana
Biggest News Aggregation in the World

Page 20 - Ip Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ip Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ip Group Today - Breaking & Trending Today

IP Group launches £20m share buyback, shares jump - Vimarsana News

IP Group launches £20m share buyback, shares jump

IP Group surged on Monday as it announced the launch of a share buyback of up to £20m.

FTSE 100 outperforms European peers - Vimarsana News

FTSE 100 outperforms European peers

Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer. The FTSE 100 index closed up 38.12 points, 0.5%, at...

London close: Stocks make small gains in wake of rate decisions - Vimarsana News

London close: Stocks make small gains in wake of rate decisions

London stocks closed with minimal changes on Monday, following a week marked by significant central bank decisions.

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury - Vimarsana News

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

/PRNewswire/ -- Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today...

IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury -December 14, 2023 at 12:44 pm EST - Vimarsana News

IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury -December 14, 2023 at 12:44 pm EST

14 Dec 2023 - Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug application ...